Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)

被引：0
|
作者：
Macarulla Mercade, T. [1 ,2 ]
Wang-Gillam, A. [3 ]
Chen, L. [4 ]
Blanc, J. [5 ]
Lee, K. [6 ]
Bodoky, G. [7 ]
Dean, A. [8 ]
Siveke, J. [9 ,10 ,11 ]
Mirakhur, B. [12 ]
Chen, J. [13 ]
de Jong, F. [14 ]
机构：
[1] Vall dHebron Univ Hosp HUVH, Barcelona, Spain
[2] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[3] Washington Univ, Div Oncol, St Louis, MO USA
[4] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan
[5] Hop Haut Leveque, Bordeaux, France
[6] Seoul Natl Univ Hosp, Seoul, South Korea
[7] Szent Laszlo Hosp, Dept Oncol, Budapest, Hungary
[8] St John God Hosp Subiaco, Subiaco, WA, Australia
[9] Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[10] German Canc Consortium DKTK, Essen, Germany
[11] German Canc Res Ctr, Essen, Germany
[12] Ipsen Biopharmaceut Inc, Basking Ridge, NJ USA
[13] Shire Plc, Cambridge, MA USA
[14] Shire Int GmbH, Glattpk Opfikon, Switzerland
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P - 150
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma
    Dietrich A. Ruess
    Frank Makowiec
    Sophia Chikhladze
    Olivia Sick
    Hartwig Riediger
    Ulrich T. Hopt
    Uwe A. Wittel
    BMC Surgery, 15
  • [22] The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma
    Ruess, Dietrich A.
    Makowiec, Frank
    Chikhladze, Sophia
    Sick, Olivia
    Riediger, Hartwig
    Hopt, Ulrich T.
    Wittel, Uwe A.
    BMC SURGERY, 2015, 15
  • [23] The Role of STIM1 in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
    Abd Elhamed, S. M.
    Aiad, H. A. S.
    Ehsan, N.
    Dawoud, M. M.
    Hemida, A. S.
    Sweed, D.
    VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) : S95 - S96
  • [24] Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: a phase 3 study of nal-IRI65-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
    Blanc, J. F.
    Hubner, R.
    Li, C-P.
    Wang-Gillam, A.
    Bodoky, G.
    Dean, A.
    Shan, Y-S.
    Jameson, G.
    Macarulla Mercade, T.
    Lee, K-H.
    Cunningham, D.
    Chiu, C-F.
    Schwartsmann, G.
    Braiteh, F.
    von Hoff, D.
    Chen, L-T.
    Mamlouk, K.
    de Jong, F.
    Siveke, J.
    ANNALS OF ONCOLOGY, 2017, 28 : 67 - U261
  • [25] p53 pathway genes' mutations as prognostic factors in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A single center study.
    Trovato, Giovanni
    Barone, Diletta
    Spring, Alexia
    Minucci, Angelo
    Chiofalo, Laura
    Perazzo, Serena
    Ceccarelli, Anna
    Di Francesco, Linda
    Cosmai, Antonia
    Messina, Gloria
    Preziosi, Alessia
    Giaco', Luciano
    Bensi, Maria
    Bagala, Cinzia
    Tortora, Giampaolo
    Salvatore, Lisa
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 771 - 771
  • [26] Population-based, real-world prognostic factors related to survival among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Yu, Kenneth H.
    Cockrum, Paul
    Surinach, Andy
    Wang Shu
    Chu, Bong Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [27] Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study
    Prenen, Hans
    Borbath, Ivan
    Paula Geboes, Karen
    Alexandre Cassier, Philippe
    Lambert, Aurelien
    Mitry, Emmanuel
    Macarulla, Teresa
    Taieb, Julien
    Blanc, Jean-Frederic
    Feliu Batlle, Jaime
    Rodriguez Garrote, Mercedes
    Pazo Cid, Roberto A.
    Valladares-Ayerbes, Manuel
    Nordbladh, Karin
    Enell Smith, Karin
    Ellmark, Peter
    Carlsson, Malin
    Pico de Coana, Yago
    Vijay Ambarkhane, Sumeet
    Van Laethem, Jean-Luc
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI ±5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
    Jean-Frederic, Blanc
    Richard, Hubner
    Li Chung-Pin
    Andrea, Wang-Gillam
    Gyorgy, Bodoky
    Andrew, Dean
    Shan Yan-Shen
    Gayle, Jameson
    Teresa, Macarulla
    Kyung-Hun, Lee
    David, Cunningham
    Chiu Chang-Fang
    Gilberto, Schwartsmann
    Fadi, Braiteh
    Daniel, Von Hoff
    Chen Li-Tzong
    Khalid, Mamlouk
    Parul, Bhargava
    Floris, de Jong
    Jens, Siveke
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma
    Kanai, Tomoya
    Ito, Zensho
    Oji, Yusuke
    Suka, Machi
    Nishida, Sumiyuki
    Takakura, Kazuki
    Kajihara, Mikio
    Saruta, Masayuki
    Fujioka, Shuichi
    Misawa, Takeyuki
    Akiba, Tadashi
    Yanagisawa, Hiroyuki
    Shimodaira, Shigetaka
    Okamoto, Masato
    Sugiyama, Haruo
    Koido, Shigeo
    ONCOLOGY LETTERS, 2018, 16 (02) : 2682 - 2692
  • [30] Nomogram for Predicting Overall Survival in Patients Treated With Liposomal Irinotecan +/- 5-Fluorouracil/Leucovorin in Metastatic Pancreatic Ductal Adenocarcinoma Previously Treated With Gemcitabine-Based Therapy in NAPOLI-1
    Bekaii-Saab, Tanios
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 14 - 14
12345